Frontlight ResearchEarly access
Metastatic breast cancer trials in China
224 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 20
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06609187 - Phase 3Taking peopleA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
- Where
- Changsha, Guangzhou
- Age
- 18 years to 75 years
- People
- 566
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06957886 - No phaseTaking peopleTo Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 200
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06784921 - Phase 2/3Taking peopleSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Where
- Anyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Liuzhou, Luoyang, Nanjing, Neijiang, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wuhan, Xi’an, Yinchuan
- Age
- 18 years to 75 years
- People
- 254
- Run by
- Shanghai Pharmaceuticals Holding Co., Ltd
See details and how to joinNCT05860465 - Phase 1/2Not yet taking people in ChinaJSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 60
- Run by
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
See details and how to joinNCT07336771 - No phaseTaking peopleA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Where
- Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jiamusi, Kunming, Lianyungang, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Ürümqi, Weifang, Wenzhou, Xiamen, Xi'an, Xi’an, Xinxiang, Xuzhou, Yinchuan, Zengzhou, Zhengzhou, Zhongshan, Zhuhai
- Age
- 18 years and over
- People
- 800
- Run by
- Daiichi Sankyo
See details and how to joinNCT06210776 - Phase 1/2Taking peopleClinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
- Where
- Beijing, Guangzhou
- Age
- 18 years to 75 years
- People
- 146
- Run by
- Shandong Suncadia Medicine Co., Ltd.
See details and how to joinNCT06167694 - Phase 2Taking peopleA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Where
- Zhejiang
- Age
- 18 years and over
- People
- 118
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07330544 - Phase 1/2Taking peopleA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 196
- Run by
- Forward Pharmaceuticals Co., Ltd.
See details and how to joinNCT07002177 - Phase 2Taking peopleEfficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 45
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07037199 - Phase 3Taking peopleA Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
- Where
- Beijing, Zhengzhou
- Age
- 18 years to 75 years
- People
- 312
- Run by
- Risen (Suzhou) Pharma Tech Co., Ltd.
See details and how to joinNCT07207070 - Phase 2Taking peoplePhase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 30
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07284836 - Phase 2Taking peopleDifferent Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Where
- Dalian, Qingdao
- Age
- 18 years to 75 years
- People
- 120
- Run by
- wanghaibo
See details and how to joinNCT07285382 - Early phase 1Taking peopleA Study of GC101 TIL in Advanced Breast Cancer (10hospital)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT05142475 - Phase 3Taking peopleAdaptive Chemotherapy for the Treatment of Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 192
- Run by
- Sun Yat-sen University
See details and how to joinNCT07088263 - Phase 3Not yet taking people in ChinaRaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
- Where
- Jinan
- Age
- 18 years to 70 years
- People
- 194
- Run by
- Pengfei Qiu
See details and how to joinNCT07269691 - Phase 2Not yet taking people in ChinaA Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Sun Yat-sen University
See details and how to joinNCT07235618 - Phase 2Taking peopleContinuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 186
- Run by
- Wenjin Yin
See details and how to joinNCT07180082 - Phase 2Taking peopleIparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 123
- Run by
- Wenjin Yin
See details and how to joinNCT07180160 - No phaseTaking peopleTrastuzumab Deruxtecan in Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 118
- Run by
- Wenjin Yin
See details and how to joinNCT07180264 - Phase 1Taking peopleA Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 21
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06493864 - Phase 2Not yet taking people in ChinaMaintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
- Where
- Shanghai
- Age
- 18 years and over
- People
- 288
- Run by
- Fudan University
See details and how to joinNCT07179939 - Phase 1Not yet taking people in ChinaA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
- Where
- Changsha
- Age
- 18 years and over
- People
- 12
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07163481 - Phase 3Taking peopleJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Where
- Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengde, Chengdu, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Guanzhou, Guiyang, Ha’erbin, Hangzhou, Hanzhou, Hefei, Hengyang, Hohhot, Jiangmen, Jinan, Jining, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Neijiang, Qingdao, Shanghai, Shantou, Shaoguan, Shengyang, Suining, Suzhou, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Xiamen, Xi'an, Xi’an, Xiangyang, Xining, Xinxiang, Xuzhou, Yongzhou, Zhaoqing, Zhengzhou, Zunyi
- Age
- 18 years and over
- People
- 400
- Run by
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
See details and how to joinNCT06079983 - No phaseTaking peopleEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
- Where
- Shijiazhuang
- Age
- 18 years and over
- People
- 420
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT05578053